STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL


USAN (OP-83)	PIVICASIRAN
PRONUNCIATION	pi vi'' kah sir’ an
THERAPEUTIC CLAIM	Treatment of metabolic dysfunction-associated steatotic liver disease (MASLD)

CHEMICAL NAMES


RNA, (Am-sp-(2′-deoxy-2′-fluoro)C-sp-Am-Um-Am-(2′-deoxy-2′-fluoro)A-Gm-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)C-Am-Um-Um-Am-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)C-Um-Am-Am-Um-Gm-sp-Gm-sp-Gm), complex with RNA (Cm-sp-Am-sp-Um-Um-Am-Gm-(2′-deoxy-2′-fluoro)G-Am-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)A-(2′-deoxy-2′-fluoro)A-Um-Gm-Um-Cm-Um-Um-Am-Um-Gm-Um) 3′-[[(2*S*,4*R*)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1)

[(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-Dgalactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*thioadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyl-3'-uridylate duplex with *all-P-ambo*-2'-*O*-methyl-*P*-thioguanylyl-(5'→3')-2'-*O*-methyl-*P*-thioguanylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*methyluridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiocytidylyl-(5'→3')-2'-*O*-methyladenosine

STRUCTURAL FORMULA




X = 2'-*O*-methylnucleotide
X = 2'-deoxy-2'-fluoronucleotide




-p- -sp-

R_1 =



R =



MOLECULAR FORMULA	$C_{531}H_{711}F_{10}N_{174}O_{321}P_{43}S_6$
MOLECULAR WEIGHT	16.4 kDa (free acid)
TRADEMARK	None as yet
SPONSOR	Regeneron Pharmaceuticals, Inc.
CODE DESIGNATIONS	ALN-PNP; ALN-519347; AD-519347
CAS REGISTRY NUMBER	2654847-29-5
UNII	8T3L374QA3
WHO NUMBER	13141

GBK